VANCOUVER, BC, Dec. 5, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that Co-Founder, President & Chief Operating Officer Kenneth Kovan will be presenting at the MedInvest Oncology Investor Conference held in New York City on December 14-15, 2022. 


In partnership with the National Foundation for Cancer Research, the MedInvest Oncology Investor Conference is the preeminent indication-specific investor conference. The attendees are active investors in the oncology space and oncology-focused companies seeking investment and partnering opportunities, and include leading life science and oncology venture capitalists, family offices, pharma executives, private and public cancer companies and foundations. The National Cancer Institute is this year's Conference Presenting Partner, with speakers such as Greg Simon, who recently was the President of the Biden Cancer "Moonshot" Initiative, leading immunologists and oncologists from Memorial Sloan Kettering and other institutions, and global pharma R&D.

Details of the presentation are as follows:

When: Wednesday, December 14, 2022 @ 4:10PM EST
Where: Dorsey & Whitney LLP, 51 West 52nd Street, New York, NY

"BioVaxys is honored to be selected to speak at the MedInvest Oncology Investor Conference alongside a prestigious group of oncologists, investors, and life science companies. We look forward to sharing how we are leveraging our haptenized protein platform to create autologous cancer immunotherapies for ovarian cancer and other malignancies," said Mr. James Passin, CEO and Co-Founder of BioVaxys.

Mr. Kovan has over 30 years of experience in biopharma. Prior to founding BioVaxys Technology Corp., he served as Corporate Development Partner with gene editing leader Horizon Discovery plc in the United Kingdom, and is Managing Principal & Owner of Bingham Hill Ventures, a life sciences advisory practice he founded in 2012. He is an experienced former biotech CEO, and founder of biotechnology companies including Avax Technologies, Inc. Mr. Kovan's professional background includes technology transfer with Thomas Jefferson University, Strategic Marketing with SmithKline Beecham, and Global New Product Development with Wyeth-Ayerst. Mr. Kovan has a broad international business background, having launched pharma brands in Latin American and Asia/Pacific markets and led pharma development projects in Europe.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. ( is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).


Signed "James Passin"

James Passin, CEO
+1 646 452 7054

Government & Media Relations
JB&A, Inc.
Davin Shinedling
+1 (647) 991-6447

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the animal model study, regulatory approval for a Phase I study of its BVX-1021 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 or SARS-CoV protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. 

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.


Cision View original content: